Minocycline
- Half-Life (t½)
- PO: 15.5h · IV: 15.5h
- Formula
- C23H27N3O7
- Molecular Weight
- 457.48 g/mol
- Aliases
- Minocin
Pharmacological Mechanism
Tetracycline — 30S ribosomal inhibitor. Higher CNS penetration than doxycycline (anti-inflammatory neuro-applications studied). First-line for inflammatory acne; vestibular side effects (~10%) worse than doxycycline. PK (Minocin label 2024, capsule formulation): Cmax 2.1–5.1 µg/mL (avg 3.5 µg/mL), Tmax 1–4 h (avg 2.1 h), t½ 11.1–22.1 h (avg 15.5 h), oral absorption virtually complete (F ≈ 0.95). High-fat meal does not change extent of absorption but delays Tmax by 1 h. Highly lipophilic of the tetracyclines — good CSF + sebaceous-gland penetration.
Half-Life & Elimination Curve (PO: 15.5h · IV: 15.5h)
Plasma (PO)t½ Decay (15.5h)
- 0×t½0h100% (0.821 mg/L)
- 1×t½15.5h50% (0.411 mg/L)
- 2×t½31h25% (0.205 mg/L)
- 3×t½46.5h12.5% (0.103 mg/L)
- 4×t½62h6.3% (51.3 µg/L)
- 5×t½3.2d3.1% (25.7 µg/L)
Dosing Guidelines
- Oral (PO): Typical 100 mg (Range: 50–200 mg)
Pharmacokinetic Parameters
- Oral (PO): Bioavailability (F): 95% · Volume of Distribution (Vd): 100 L · Absorption (ka): 1 h⁻¹ (t½ka ≈ 42m) [PMID 33168615]
- Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 100 L [PMID 33168615]
Pathways It Modulates
Target Organ Systems
- Integumentary System
- Immune & Hematologic
Chemical Structure & Identifiers
- InChIKey: FFTVPQUHLQBXQZ-KVUCHLLUSA-N
- SMILES: CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)N(C)C
References